x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DPP-001272
| Product Overview | |
|---|---|
| Species | Human |
| Expression System | Wheat germ |
| Format | Liquid |
| Purity | ≥97% by SDS-PAGE |
| Nature | Recombinant |
| Target Information | |
|---|---|
| Gene Name | TCF7L2 |
| UniProt No. | Q9NQB0 |
| Gene ID | 6934 |
| Alternative Names | HMG box transcription factor 4; hTCF 4; hTCF-4; T cell factor 4; T cell specific HMG box; T cell specific transcription factor 4; T-cell factor 4; T-cell-specific transcription factor 4; TCF 4; TCF-4; TCF4; TCF7L2; TCF7L2 protein; TF7L2_HUMAN; Transcription factor 7 like 2; Transcription factor 7 like 2 T cell specific HMG box; Transcription factor 7-like 2 |
| Function | Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine. |
| Involvement In Disease | Constitutive activation and subsequent transactivation of target genes may lead to the maintenance of stem-cell characteristics (cycling and longevity) in cells that should normally undergo terminal differentiation and constitute the primary transforming event in colorectal cancer (CRC).Genetic variations in TCF7L2 are associated with susceptibility to non-insulin-dependent diabetes mellitus (NIDDM). NIDDM is characterized by an autosomal dominant mode of inheritance, onset during adulthood and insulin resistance. |
| Cellular Localization | Nucleus > PML body. Diffuse pattern. Colocalizes with SUMO1 and PIAS4 in a subset of PML (promyelocytic leukemia) nuclear bodies. |
| Protein Length | Full length protein |
| Sequence | MPQLNGGGGDDLGANDELISFKDEGEQEEKSSENSSAERDLADVKSSLVN ESETNQNSSSDSEAERRPPPRSESFRDKSRESLEEAAKRQDGGLFKGPPY PGYPFIMIPDLTSPYLPNGSLSPTARTYLQMKWPLLDVQAGSLQSRQALK DARSPSPAHIVSNKVPVVQHPHHVHPLTPLITYSNEHFTPGNPPPHLPAD VDPKTGIPRPPHPPDISPYYPLSPGTVGQIPHPLGWQGQPVYPITTGGFR HPYPTALTVNASMSRFPPHMVPPHHTLHTTGIPHPAIVTPTVKQESSQSD VGSLHSSKHQDSKKEEEKKKPHIKKPPNAFMLYMKEMRAKVVAECTLKES AAINQILGRRWHALSREEQAKYYELARKERQLHMQLYPGWSARDNYGKKK KRKRDKQPGETNEHSECFLNPCLSLPPITGEKKSAFATYKVKAAASAHPL QMEAY,Belongs to the TCF/LEF family. Contains 1 HMG box DNA-binding domain. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped on dry ice. |
| Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
